| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim |
NCT01577550: Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis |
|
|
| Completed | 1 | 39 | US, Europe | BI 655066 (very high i.v. dose), ABBV-066, risankizumab, Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose) | AbbVie, Boehringer Ingelheim | Psoriasis | 10/13 | 05/14 | | |
NCT02596217: Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers |
|
|
| Completed | 1 | 80 | Japan, RoW | ABBV-066, BI 655066, risankizumab, Placebo | AbbVie, Boehringer Ingelheim | Healthy | 06/17 | 06/17 | | |
NCT02772601: This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis |
|
|
| Completed | 1 | 21 | Europe | Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam, Risankizumab, ABBV-066, BI 655066 | AbbVie, Boehringer Ingelheim | Psoriasis | 06/17 | 09/17 | | |
NCT05283694: A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants |
|
|
| Completed | 1 | 48 | US | risankizumab, ABBV-066, SKYRIZI | AbbVie | Healthy Volunteers | 06/18 | 06/18 | | |
NCT05305222: A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab |
|
|
| Completed | 1 | 17 | US | Risankizumab, SKYRIZI, ABBV-066, Placebo | AbbVie | Healthy Volunteers | 06/18 | 06/18 | | |
NCT05283681: A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants |
|
|
| Completed | 1 | 226 | US | Risankizumab, ABBV-066, SKYRIZI | AbbVie | Healthy Volunteers | 11/19 | 11/19 | | |
NCT05268068: A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China |
|
|
| Completed | 1 | 30 | RoW | Risankizumab, ABBV-066, SKYRIZI | AbbVie | Healthy Volunteers | 04/20 | 04/20 | | |
NCT05274087: Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers |
|
|
| Completed | 1 | 30 | US | Risankizumab, SKYRIZI | AbbVie | Healthy Volunteers | 04/21 | 04/21 | | |
NCT05274100: Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants |
|
|
| Completed | 1 | 394 | US | Risankizumab, SKYRIZI | AbbVie | Healthy Volunteers | 07/21 | 07/21 | | |
NCT05083078: A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis |
|
|
| Terminated | 1 | 11 | Europe | Guselkumab, Tremfya, CNTO1959, Risankizumab, Skyrizi | Janssen Research & Development, LLC | Arthritis, Psoriatic, Healthy | 07/22 | 07/22 | | |
M19-974, NCT04254783: A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease |
|
|
| Completed | 1 | 20 | Europe, US, RoW | Risankizumab, SKYRIZI, ABBV-066, Cytochrome P450 (CYP) Substrates | AbbVie | Ulcerative Colitis (UC), Crohn's Disease | 10/22 | 10/22 | | |
NCT05567029: Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers. |
|
|
| Completed | 1 | 198 | US | Risankizumab Dose A, Risankizumab Dose B | AbbVie | Healthy Volunteers | 04/23 | 04/23 | | |
NCT06054425: A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults |
|
|
| Completed | 1 | 48 | US | Risankizumab | AbbVie | Healthy Volunteers | 05/24 | 05/24 | | |
NCT06487572: A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants |
|
|
| Completed | 1 | 60 | US | Risankizumab, ABBV-066, SKYRIZI | AbbVie | Healthy Volunteers | 02/25 | 02/25 | | |
NCT06571266: A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants |
|
|
| Completed | 1 | 231 | US | Risankizumab, ABBV-066, SKYRIZI | AbbVie | Healthy Volunteers | 04/25 | 04/25 | | |
NCT06937619: A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants |
|
|
| Completed | 1 | 263 | US | Risankizumab, SKYRIZI, ABBV-066 | AbbVie | Healthy Volunteer | 11/25 | 11/25 | | |
NCT06946524: A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants |
|
|
| Completed | 1 | 59 | US | Risankizumab, SKYRIZI | AbbVie | Healthy Volunteers | 11/25 | 11/25 | | |
NCT07007091: A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants |
|
|
| Active, not recruiting | 1 | 260 | US | Risankizumab | AbbVie | Healthy Volunteers | 12/25 | 12/25 | | |
NCT07258745: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants |
|
|
| Recruiting | 1 | 213 | Europe | SKYRIZI, CKD-704 | Chong Kun Dang Pharmaceutical | Psoriasis | 09/26 | 09/26 | | |
